Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:37:52.760Z.
Calculation as of: 2026-10-06T16:37:52.760Z.
Quote observation: 2026-10-06T16:34:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0dc40ddd6b0c815ea8fb06d6c0f10798674f4babd9a38c246e46e89e51900236
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$49.98M
Price/FCF Ratio
N/A
TTM Avg
13.23
3Y Avg
14.22
5Y Avg
14.22
Market Cap
$47.83M
Price/FCF Ratio
N/A
TTM Avg
99.30
3Y Avg
99.30
5Y Avg
93.30
Market Cap
$51.08M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | $49.00M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $49.98M | N/A | 13.23 | 14.22 | 14.22 |
| Precision Optics Corporation, Inc. (POCI)vs › | $47.83M | N/A | 99.30 | 99.30 | 93.30 |
| Apollomics, Inc. (APLM)vs › | $49.89M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $50.37M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $50.51M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $51.05M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.08M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 2.62 | 2.45 | 5.29 | 4.64 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
